95 results
424B3
QLGN
Qualigen Therapeutics Inc
3 May 24
Prospectus supplement
1:50pm
expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among other things, potential future development, testing
POS AM
QLGN
Qualigen Therapeutics Inc
30 Apr 24
Prospectus update (post-effective amendment)
6:58pm
,” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions
8-K
EX-99.1
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
to the Companies’ prospects and strategy for development of the Companies’ medical devices and therapeutic drug candidates. Actual events or results may differ
8-K
EX-99.1
0i7cs9sao
14 Nov 23
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
5:10pm
8-K
EX-99.1
uzq75bqgkue5yn57xk
8 Nov 23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2:16pm
8-K
EX-99.1
j5f2xsqnc
15 Aug 23
Results of Operations and Financial Condition
10:04am
8-K
EX-99.1
096 8k964j
1 Aug 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
zeoho26 u6
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
8-K
ldv7ao7levauql np0g8
26 Jun 23
Departure of Directors or Certain Officers
5:25pm
8-K
octz0t2
19 May 23
Departure of Directors or Certain Officers
8:20am